Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs 16th Winter Workshop of the Canadian-Rheumatology-Association Gomez-Reino, J. J., Nair, B., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Genovese, M. J RHEUMATOL PUBL CO. 2008: 1216–16
View details for Web of Science ID 000256503900182